1.Laparoscopy in the diagnosis and treatment of unexplained acute right lower abdominal pain in women
Zhengang SUN ; Shanyan ZHANG ; Zhiqi YANG
Chinese Journal of Minimally Invasive Surgery 2005;0(07):-
Objective To evaluate the significance of laparoscopy in the diagnosis and treatment of unexplained acute right lower abdominal pain in women. Methods Clinical data of 52 women with unexplained acute right lower abdominal pain from April 1999 to April 2004 were retrospectively analyzed. Results Diagnosis was clarified under laparoscope in all the 52 patients, including 28 cases of acute appendicitis, 18 cases of acute pelvic inflammatory disease, 3 cases of ovarian cyst pediculotorsion, 2 cases of right tubal pregnancy, and 1 case of Crohn’s disease with iliac perforation. With exception of a conversion to open surgery in 3 patients, laparoscopic treatment was successfully completed in the remaining 49 patients. No surgical complications occurred. The patients were discharged from the hospital 2~6 days postoperatively. Conclusions Laparoscopy is a timely, safe and effective alternative for the diagnosis and treatment of unexplained acute lower right abdominal pain in women.
2.A Study of Apoptosis in Renal Tissue of Diffuse Proliferative Lupus Nephritis
Wen SHEN ; Fuming LU ; Xiurong ZHANG ; Muyi GUO ; Shanyan LIN
Fudan University Journal of Medical Sciences 2001;28(1):35-38
Purpose To evaluate apoptosis in renal tissue of diffuse proliferative lupus nephritis and therelationship between the existence of apoptosis cells in renal tissue and histopathological or clinical changes.Methods Apoptosis was detected by in situ nick-end labeling techniques (TUNEL) in renal biopsies from 25patients with type Ⅳ LN, 12 patients with IgAN, 4 patients with MsPGN, and 3 patients with APSGN. Normalrenal tissue obtained at nephrectorny for hypemephroma in 4 adults was used as control. In addition, proliferatingcells were identified by proliferating cell nuclear antigen(PCNA) in these patients. Results Compared to otherproliferative glomerulonephritis and control,the patients with lupus nephritis had less apoptosis cells, higher ratio ofPCNA+ cells/TdT+ cells/(P/T) in renal tissues;Ratio of P/T in glomeruli and tubulointerstitium correlated withthe chronicity index, r=0. 498 3(P = 0. 013 2), r = 0. 839 9(P< 0.001 ), r = 0. 661 4(P = 0. 003 3),respectively. Ratio of P/T in glomerulus and tubule had positive correlation with 24 hour urinary protein, r =0.855 4(P<0.001),r=0.713 4(P=0. 001); negative correlation with Ccr, r = - 0. 488 0(P =0. 013 3)and r = - 0. 722 9(P = 0. 001), which in tubules positively correlated with Scr, r = 0. 410 7 (P = 0.041 4 ).Conclusions Apoptosis is insufficient in proliferative lupus nephritis. Intense proliferation without followingincrease in apoptosis may be related to chronic progressive renal histopatholcgical changes.
3.Clinical Study on Treatment of Iliac-Femoral Venous Thrombus Via Double Femoral Veins
Haozhou WANG ; Shanyan LIANG ; Shuhou WANG ; Wenbin ZHANG ; Junsheng KANG
Journal of Practical Radiology 2000;0(02):-
Objective To evaluate the efficiency of treatment of iliac-femoral venous thrombus(I-FVT)via double femoral veins.Methods Eighteen patients with I-FVT were treated with implantation of inferior vena caval filter,catheter-directed cut,balloon-directed extend and drag.Some patients were treated with ATD or OASIS catheter.After operation,the catheter was kept in iliac-femoral veins for one to six days.Meanwhile,strict anti-coagulation was necessary.Results The treatment was successful in seventeen patients,the iliac-femoral veins were patent after the opration.Swollen symptom of lower limb and pain disappeared in fifteen patients,swollen symptom of lower limb became better in two patients.The treatment was fail in one patient.Follow-up study showed no pulmonary embolization or recrudescence in all eighteen patients.Conclusion The treatment of I-FVT via double femoral veins is a safe and effective method,there are no serious complications.
4.Action of blocking renin-angiotensin system on protein kinase C?Ⅱ isoform in renal tissue of diabetic rats
Li ZHANG ; Ji MA ; Yong GU ; Shanyan LIN
Chinese Journal of Endocrinology and Metabolism 1985;0(01):-
Objective To investigate the expression and translocation of protein kinase C (PKC) ?Ⅱ isoform in renal tissue of diabetic rats and the effects of blocking renin-angiotensin system (RAS) on them. Methods Diabetic rats induced with streptozotocin were randomized to 4 groups. (1) Diabetic control without treatment. (2) Treatment with irbesartan (40 mg?kg -1 ?d -1 ). (3)Treatment with fosinopril (40 mg?kg -1 ?d -1 ) and (4) Treatment with a combination of irbesartan and fosinopril (20 mg?kg -1 ?d -1 each). Six normoglycemic rats served as normal control. After 4 weeks, blood glucose and insulin were measured and expression and translocation of PKC?Ⅱ in renal cortex and medulla were assessed by immunohistochemistry and Western blot. Results The expressions of total and membrane fraction in renal cortex of diabetic control rats weredecreasedto66.0%and50.0% of the values of normal control rats respectively (both P
5.Mediating effect of work-family conflict and work-family enrichment in the relationship between job demands and subjective well-being among nurses
Yujie ZHANG ; Shanyan LEI ; Fang YANG
China Occupational Medicine 2023;50(2):170-174
6.Role of endothelial bioreactor device in sepsis porcine model
Junfeng LIU ; Yi PING ; Qionghong XIE ; Jiaying ZHANG ; Li YOU ; Jianyong ZHONG ; Weimin DIANG ; Yi LI ; Bobin CHEN ; Yong GU ; Shanyan DIN ; Feng DING
Chinese Journal of Emergency Medicine 2010;19(1):47-51
Objective To investigate the role of endothelial bioreacter device in sepsis porcine model.Method Sepsis porcine model was induced gy established endotoxin (LPS,0.25 mg·kg~(-1)) in healthy hybrid swines. The animals were randomly divided(random number) into endothelial bioreactor device group(EBR group) and sham circulation group( Sham group)( n = 6, respectively). After the infusion of endotoxin, extracorporeal circulation was started with the blood flow of 30 mL/min. The blood went through the endothelial bioreactor, then went back to the body via internal jugular vein in the EBR group. The bioreactor with the same size and without endothelial cells(ECs) was used in the sham group. Hemodynamic variables, blood biochemistry, inflammatory markers, Endothelin-1(ET-11) and yon Willebrand Factor(vWF) were examined just before and every hour after the injection. When the survival time of the animals was recorded,the animals were sacrificed to calculate the lung injury score. The time-dependent hemodynamics and cytokine data were compared between groups by repeated measurement ANOVA .Student's t -test was used to analyze the survival time. Results The mean artetial blood pressure (MAP) remarkably decreased in both groups after LPS injection, while the decreasing rate in EBR group was significantly lower than that in control group after 2 hours( P < 0.05). The ET- 1 level in EBR group increased after a slight decrease at the beginning, while that in the sham group went on increasing(P<0.01). The vWF levels increased first, then returned to the baseline in the sixth hour in both groups, while the change in EBR group was significantly less than that in the sham group(P<0.05). The Lung Injury Score in EBR-treated group was significantly lower than that in the sham group(6.1 ± 0.9 vs. 8.2 ± 1. 0, P < 0.05). These physiologic and biochemical alterations were associated with a significant advantage to the survivals in the EBR group when compared with the control sham group(6.7 ± 1.32 vs. 5.2 ± 0.61 h, P < 0.01 ). Conclusions Timely intervention in endotoxin shock with EC therapy by using tissue-engineered bioreactor may improve cardiovascular performance and alter the natural course of this disease process, probably via modulating ioflammation and coagulation cascades.
7.Detection rate of depression symptoms and its influencing factors in breast cancer patients during chemotherapy in China: a meta-analysis and systematic review
Yujie ZHANG ; Shanyan LEI ; Fang YANG
Chinese Journal of Health Management 2023;17(8):608-613
Objective:To systematically evaluate the prevalence of depressive symptoms and its influencing factors in breast cancer patients during chemotherapy in China.Methods:The databases such as CNKI, Wanfang Data, VIP, PubMed, Web of Science and Embase were searched with retrieval terms of breast cancer, breast tumor, chemotherapy, depressive symptom, mental health, melancholia, Chinese, etc for the literature related to the prevalence of depressive symptoms in breast cancer patients during chemotherapy in China. Relevant literature from the establishment of the databases to August 2022 were retrieved. Two researchers screened the literature independently, extracted data and evaluated the risk of bias in the included studies, and prevalence of depressive symptoms and its influencing factors in breast cancer patients during chemotherapy in China were systematically evaluated by using RevMan 5.3 and Stata 14.1 software.Results:A total of 18 studies were included, including 2 678 subjects. Meta-analysis results showed that the prevalence of depressive symptom in breast cancer patients in China was 51.60% (95% CI: 44.10%-55.10%). The results of subgroup analysis showed that age ( OR=2.55, 95% CI: 1.26-5.14), educational level ( OR=2.01, 95% CI: 1.01-3.98), marital status ( OR=0.50, 95% CI: 0.29-0.86), occupational status ( OR=3.29, 95% CI: 1.04-10.46), clinical staging ( OR=0.32, 95% CI: 0.22-0.46) and frequency of chemotherapy ( OR=0.39, 95% CI: 0.17-0.86) were the influencing factors of depressive symptoms in breast cancer patients during chemotherapy in China (all P<0.05). Conclusions:The prevalence of depressive symptoms in breast cancer patients during chemotherapy in China is high. Breast cancer patients undergoing chemotherapy who are under 50 years old, having a high school education or lower, are not married, currently employed, and in clinical stage 3-4 and receiving more than 4 chemotherapy cycles are more likely to experience depressive symptoms.
8.Research progress on interferon λ in chronic hepatitis B
Chanyuan YE ; Shanyan ZHANG ; Xiaoli ZHANG ; Jueqing GU ; Yida YANG
Chinese Journal of Clinical Infectious Diseases 2020;13(3):228-233
Hepatitis B is a major public health problem in China. Nucleoside/nucleotide analogues and interferon(IFN) can effectively inhibit the replication of hepatitis B virus, but the treatment effect is still not so effective because cccDNA cannot be completely removed. IFNλ is a newly discovered family of cytokines that induces antiviral, antiproliferative and antitumor effects by activating the Jak-STAT pathway. Recent studies have found that IFNλ is also of great significance in hepatitis B as a therapeutic agent and immunological indicator. IFNλ can effectively inhibit the replication of hepatitis B virus, while the gene polymorphisms of IFNλ are closely related to prognosis and susceptibility to hepatitis B; and IFNλ also shows a certain anti-tumor activity in hepatitis B-related hepatocellular carcinoma. IFNλ is expected to be used as a clinical adjuvant treatment for patients with hepatitis B. This article describes the current research progress on IFNλ in hepatitis B.
9.Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood-brain barrier and exhibits potent activity against glioblastoma.
Yingqiang LIU ; Zhengsheng ZHAN ; Zhuang KANG ; Mengyuan LI ; Yongcong LV ; Shenglan LI ; Linjiang TONG ; Fang FENG ; Yan LI ; Mengge ZHANG ; Yaping XUE ; Yi CHEN ; Tao ZHANG ; Peiran SONG ; Yi SU ; Yanyan SHEN ; Yiming SUN ; Xinying YANG ; Yi CHEN ; Shanyan YAO ; Hanyu YANG ; Caixia WANG ; Meiyu GENG ; Wenbin LI ; Wenhu DUAN ; Hua XIE ; Jian DING
Acta Pharmaceutica Sinica B 2023;13(12):4748-4764
Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults and is poorly controlled. Previous studies have shown that both macrophages and angiogenesis play significant roles in GBM progression, and co-targeting of CSF1R and VEGFR is likely to be an effective strategy for GBM treatment. Therefore, this study developed a novel and selective inhibitor of CSF1R and VEGFR, SYHA1813, possessing potent antitumor activity against GBM. SYHA1813 inhibited VEGFR and CSF1R kinase activities with high potency and selectivity and thus blocked the cell viability of HUVECs and macrophages and exhibited anti-angiogenetic effects both in vitro and in vivo. SYHA1813 also displayed potent in vivo antitumor activity against GBM in immune-competent and immune-deficient mouse models, including temozolomide (TMZ) insensitive tumors. Notably, SYHA1813 could penetrate the blood-brain barrier (BBB) and prolong the survival time of mice bearing intracranial GBM xenografts. Moreover, SYHA1813 treatment resulted in a synergistic antitumor efficacy in combination with the PD-1 antibody. As a clinical proof of concept, SYHA1813 achieved confirmed responses in patients with recurrent GBM in an ongoing first-in-human phase I trial. The data of this study support the rationale for an ongoing phase I clinical study (ChiCTR2100045380).